LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Search

Charles River Laboratories International Inc

Aperta

SettoreSettore sanitario

162.14 -0.62

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

159.54

Massimo

167.54

Metriche Chiave

By Trading Economics

Entrata

2.9M

56M

Vendite

-27M

1B

EPS

2.43

Margine di Profitto

5.529

Dipendenti

18,700

EBITDA

-23M

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+22.87% upside

Dividendi

By Dow Jones

Utili prossimi

6 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-862M

7.9B

Apertura precedente

162.76

Chiusura precedente

162.14

Notizie sul Sentiment di mercato

By Acuity

44%

56%

126 / 351 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 feb 2026, 23:55 UTC

Discorsi di Mercato

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 feb 2026, 23:53 UTC

Discorsi di Mercato

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 feb 2026, 23:53 UTC

Discorsi di Mercato

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 feb 2026, 23:51 UTC

Discorsi di Mercato

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 feb 2026, 23:35 UTC

Discorsi di Mercato

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 feb 2026, 23:21 UTC

Utili

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 feb 2026, 23:20 UTC

Utili

Nickel Industries 2025 Operating Profit US$126.4 Million

22 feb 2026, 23:19 UTC

Utili

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 feb 2026, 23:19 UTC

Utili

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 feb 2026, 23:18 UTC

Utili

Nickel Industries Won't Pay a Final Dividend

22 feb 2026, 23:16 UTC

Utili

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 feb 2026, 21:35 UTC

Utili

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 feb 2026, 21:34 UTC

Utili

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 feb 2026, 21:34 UTC

Utili

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 feb 2026, 21:33 UTC

Utili

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 feb 2026, 21:33 UTC

Utili

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 feb 2026, 21:28 UTC

Utili

Ampol Final Dividend A$0.60/Share

22 feb 2026, 21:28 UTC

Utili

Ampol FY Revenue A$31.37 Billion, Down 10%

22 feb 2026, 21:28 UTC

Utili

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 feb 2026, 21:28 UTC

Utili

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 feb 2026, 14:31 UTC

Acquisizioni, Fusioni, Takeovers

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 feb 2026, 05:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

20 feb 2026, 23:12 UTC

Acquisizioni, Fusioni, Takeovers

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 feb 2026, 22:12 UTC

Utili

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 feb 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

20 feb 2026, 21:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

20 feb 2026, 21:23 UTC

Utili

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 feb 2026, 21:20 UTC

Discorsi di Mercato

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 feb 2026, 21:01 UTC

Acquisizioni, Fusioni, Takeovers

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 feb 2026, 20:38 UTC

Discorsi di Mercato

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

22.87% in crescita

Previsioni per 12 mesi

Media 207.56 USD  22.87%

Alto 265 USD

Basso 175 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

8

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

126 / 351 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat